• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

韩国泌尿科医生对良性前列腺增生症诊断和治疗模式的看法:一项全国性调查。

Korean urologist's view of practice patterns in diagnosis and management of benign prostatic hyperplasia: a nationwide survey.

机构信息

Department of Urology, Hallym University College of Medicine, Chuncheon, Korea.

出版信息

Yonsei Med J. 2010 Mar;51(2):248-52. doi: 10.3349/ymj.2010.51.2.248. Epub 2010 Feb 12.

DOI:10.3349/ymj.2010.51.2.248
PMID:20191018
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2824872/
Abstract

PURPOSE

In Korea, there was no specific guidelines for the management of benign prostatic hyperplasia (BPH). We reviewed the practice patterns of Korean urologists in the management of BPH and aimed to describe the need to develop specific guidelines.

MATERIALS AND METHODS

A probability sample was taken from the Korean Urological Association Registry of Physicians, and a structured questionnaire, that explored practice patterns in the management of BPH, was mailed to a random sample of 251 Korean urologists.

RESULTS

For the initial evaluation of BPH, most urologists routinely performed prostatic specific antigen (PSA) (96.4%), digital rectal exam (94.4%), international prostate symptom score (IPSS) (83.2%) and transrectal ultrasound (79.2%). Symptom assessment (36.4%) followed by transrectal ultrasound of prostate (TRUS) (20.0%) was considered as the most important diagnostic examination affecting the decision about individual treatment options. Almost all urologists (92.2%) chose medical treatment as the first-line treatment option for uncomplicated BPH with moderate symptoms. Of the respondents, 57.2% had prescribed alpha blocker and 41.6% alpha blocker plus 5-alpha reductase inhibitors as the medical treatment option for BPH. The prescription of 5-ARIs was dependent on the size of the prostate and the severity of symptoms.

CONCLUSION

The results of our current survey provide useful insight into variations in the clinical practice of Korean urologists. They also indicate the need to develop further practical guidelines based on solid clinical data and to ensure that these guidelines are widely promoted and accepted by the urological community.

摘要

目的

在韩国,尚无针对良性前列腺增生(BPH)管理的具体指南。我们回顾了韩国泌尿科医生在 BPH 管理中的实践模式,并旨在描述制定具体指南的必要性。

材料与方法

从韩国泌尿科医师协会医师注册处抽取概率样本,并向 251 名韩国泌尿科医师随机样本邮寄了一份探讨 BPH 管理实践模式的结构化问卷。

结果

对于 BPH 的初始评估,大多数泌尿科医生常规进行前列腺特异性抗原(PSA)(96.4%)、直肠指检(94.4%)、国际前列腺症状评分(IPSS)(83.2%)和经直肠超声(TRUS)(79.2%)检查。症状评估(36.4%)后进行前列腺经直肠超声检查(TRUS)(20.0%)被认为是影响个体治疗方案决策的最重要的诊断检查。几乎所有泌尿科医生(92.2%)都选择药物治疗作为有中度症状的非复杂 BPH 的一线治疗方案。在受访者中,57.2%开了α受体阻滞剂,41.6%开了α受体阻滞剂加 5α-还原酶抑制剂作为 BPH 的药物治疗选择。5-ARIs 的处方取决于前列腺的大小和症状的严重程度。

结论

我们当前调查的结果提供了对韩国泌尿科医生临床实践差异的有用见解。它们还表明,需要根据可靠的临床数据制定进一步的实用指南,并确保这些指南得到泌尿科界的广泛推广和认可。

相似文献

1
Korean urologist's view of practice patterns in diagnosis and management of benign prostatic hyperplasia: a nationwide survey.韩国泌尿科医生对良性前列腺增生症诊断和治疗模式的看法:一项全国性调查。
Yonsei Med J. 2010 Mar;51(2):248-52. doi: 10.3349/ymj.2010.51.2.248. Epub 2010 Feb 12.
2
The urologist's view of male overactive bladder: discrepancy between reality and belief in practical setting.泌尿科医生对男性膀胱过度活动症的看法:实际情况与实际信念之间的差异。
Yonsei Med J. 2010 May;51(3):432-7. doi: 10.3349/ymj.2010.51.3.432.
3
Patterns in the diagnosis and management of benign prostatic hyperplasia in a country that does not have country-specific clinical practice guidelines.在一个没有针对该国的临床实践指南的国家中,良性前列腺增生的诊断和管理模式。
Yonsei Med J. 2007 Apr 30;48(2):281-8. doi: 10.3349/ymj.2007.48.2.281.
4
[Do urologists apply benign prostatic hyperplasia clinical practice guidelines? Survey on the complementary investigation request modalities in France].[泌尿外科医生是否应用良性前列腺增生临床实践指南?法国补充检查申请方式的调查]
Prog Urol. 2004 Jun;14(3):320-5.
5
[Factors determining treatment strategies for patients with benign prostatic hyperplasia. The DUO study].[良性前列腺增生患者治疗策略的决定因素。DUO研究]
Presse Med. 2007 May;36(5 Pt 1):755-63. doi: 10.1016/j.lpm.2006.12.027. Epub 2007 Feb 27.
6
Comparative analysis of benign prostatic hyperplasia management by urologists and nonurologists: a Korean nationwide health insurance database study.泌尿科医生与非泌尿科医生对良性前列腺增生症治疗的比较分析:一项韩国全国健康保险数据库研究
Korean J Urol. 2015 Mar;56(3):233-9. doi: 10.4111/kju.2015.56.3.233. Epub 2015 Mar 3.
7
Management of symptomatic BPH in Italy: who is treated and how?意大利症状性良性前列腺增生症的管理:哪些人接受治疗以及如何治疗?
Eur Urol. 1999;36 Suppl 3:28-32. doi: 10.1159/000052346.
8
A nationwide survey of practicing urologists: current management of benign prostatic hyperplasia and clinically localized prostate cancer.一项针对执业泌尿科医生的全国性调查:良性前列腺增生症和临床局限性前列腺癌的当前管理情况
J Urol. 1997 Aug;158(2):488-91; discussion 492. doi: 10.1016/s0022-5347(01)64510-5.
9
Practice patterns of Canadian urologists in benign prostatic hyperplasia and prostate cancer. Canadian Prostate Health Council.加拿大泌尿外科医生在良性前列腺增生和前列腺癌方面的诊疗模式。加拿大前列腺健康委员会。
J Urol. 2000 Feb;163(2):499-502.
10
Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry.泌尿科医生和初级保健医生对良性前列腺增生的评估和管理:来自观察性 BPH 登记处的实践模式。
J Urol. 2011 Sep;186(3):971-6. doi: 10.1016/j.juro.2011.04.081. Epub 2011 Jul 24.

引用本文的文献

1
Drug Prescription Patterns During Initial Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Study Based on Health Insurance Review and Assessment Database.药物处方模式在与良性前列腺增生相关的下尿路症状初始治疗中的应用:一项基于健康保险审查和评估数据库的研究。
J Korean Med Sci. 2022 Mar 28;37(12):e95. doi: 10.3346/jkms.2022.37.e95.
2
Adherence of Indonesian urologists to practice guidelines for the management of benign prostatic hyperplasia.印度尼西亚泌尿外科医生对良性前列腺增生管理实践指南的遵循情况。
Prostate Int. 2019 Mar;7(1):35-40. doi: 10.1016/j.prnil.2018.01.003. Epub 2018 Feb 9.
3

本文引用的文献

1
The evolution of KTP laser vaporization of the prostate.前列腺的KTP激光汽化术的发展历程。
Yonsei Med J. 2008 Apr 30;49(2):189-99. doi: 10.3349/ymj.2008.49.2.189.
2
[German guidelines for the assessment of BPH. What's new in 2007?].[德国良性前列腺增生评估指南。2007年有哪些新内容?]
Urologe A. 2008 Feb;47(2):149-54. doi: 10.1007/s00120-007-1609-x.
3
Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey.了解欧洲患者和医生对良性前列腺增生的看法:行为与教育前列腺研究(PROBE)调查。
Voided volume < 150 mL on initial uroflowmetry in men with storage symptoms: Is it an unreliable test result or a sign of severe storage symptoms?
初始尿流率测定时男性排空量 < 150 mL:这是一个不可靠的检测结果,还是严重储存症状的迹象?
PLoS One. 2019 Jan 7;14(1):e0207208. doi: 10.1371/journal.pone.0207208. eCollection 2019.
4
Safety and Effectiveness of Once-Daily Tadalafil (5 mg) Therapy in Korean Men with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms in a Real-World Clinical Setting: Results from a Post-Marketing Surveillance Study.他达拉非(5毫克)每日一次治疗韩国良性前列腺增生/下尿路症状男性患者在真实临床环境中的安全性和有效性:一项上市后监测研究的结果
World J Mens Health. 2018 May;36(2):161-170. doi: 10.5534/wjmh.17017. Epub 2017 Sep 6.
5
Nationwide incidence and treatment pattern of benign prostatic hyperplasia in Korea.韩国良性前列腺增生的全国发病率和治疗模式。
Investig Clin Urol. 2016 Nov;57(6):424-430. doi: 10.4111/icu.2016.57.6.424. Epub 2016 Nov 1.
6
Comparative analysis of benign prostatic hyperplasia management by urologists and nonurologists: a Korean nationwide health insurance database study.泌尿科医生与非泌尿科医生对良性前列腺增生症治疗的比较分析:一项韩国全国健康保险数据库研究
Korean J Urol. 2015 Mar;56(3):233-9. doi: 10.4111/kju.2015.56.3.233. Epub 2015 Mar 3.
7
The Efficacy and Safety of Tadalafil 5 mg Once Daily in Korean Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: An Integrated Analysis.每日一次 5 毫克他达拉非治疗有下尿路症状的韩国良性前列腺增生症男性的疗效和安全性:综合分析。
World J Mens Health. 2014 Apr;32(1):28-35. doi: 10.5534/wjmh.2014.32.1.28. Epub 2014 Apr 25.
8
Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil.亚洲男性良性前列腺增生(BPH)继发的下尿路症状(LUTS)以及伴有勃起功能障碍的LUTS/BPH:聚焦他达拉非的系统评价
World J Mens Health. 2013 Dec;31(3):193-207. doi: 10.5534/wjmh.2013.31.3.193. Epub 2013 Dec 24.
9
Analysis of prescriptions of alpha-blockers and phosphodiesterase 5 inhibitors from the urology department and other departments.分析泌尿外科及其他科室开具的α受体阻滞剂和磷酸二酯酶 5 抑制剂处方
Int Neurourol J. 2011 Dec;15(4):216-21. doi: 10.5213/inj.2011.15.4.216. Epub 2011 Dec 31.
10
Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia.5-α 还原酶抑制剂对良性前列腺增生患者储存症状的影响。
Int Neurourol J. 2011 Sep;15(3):152-7. doi: 10.5213/inj.2011.15.3.152. Epub 2011 Sep 30.
Int J Clin Pract. 2008 Jan;62(1):18-26. doi: 10.1111/j.1742-1241.2007.01635.x. Epub 2007 Nov 19.
4
Evidence-based guidelines for the management of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary.意大利非复杂性良性前列腺增生相关下尿路症状管理的循证指南:最新总结
Curr Med Res Opin. 2007 Jul;23(7):1715-32. doi: 10.1185/030079907x210534.
5
Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.韩国良性前列腺增生男性血清前列腺特异性抗原与前列腺体积的关系:一项多中心研究。
BJU Int. 2006 Apr;97(4):742-6. doi: 10.1111/j.1464-410X.2006.06016.x.
6
Canadian guidelines for the management of benign prostatic hyperplasia.加拿大良性前列腺增生管理指南。
Can J Urol. 2005 Jun;12(3):2677-83.
7
EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines).欧洲泌尿外科学会(EAU)2004年关于疑似良性前列腺梗阻的男性下尿路症状的评估、治疗及随访指南(BPH指南)
Eur Urol. 2004 Nov;46(5):547-54. doi: 10.1016/j.eururo.2004.07.016.
8
[International comparison of guidelines for the management of benign prostatic hyperplasia: use of a validated generic tool].[良性前列腺增生管理指南的国际比较:使用经过验证的通用工具]
Prog Urol. 2004 Feb;14(1):29-32.
9
A review of guidelines on benign prostatic hyperplasia and lower urinary tract symptoms: are all guidelines the same?良性前列腺增生与下尿路症状指南综述:所有指南都一样吗?
BJU Int. 2003 Dec;92(9):937-42. doi: 10.1111/j.1464-410x.2003.04529.x.
10
AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations.美国泌尿外科学会良性前列腺增生管理指南(2003年)。第1章:诊断与治疗建议。
J Urol. 2003 Aug;170(2 Pt 1):530-47. doi: 10.1097/01.ju.0000078083.38675.79.